On April 28, 2026 the Drug Enforcement Administration placed FDA-approved drug products containing marijuana, along with marijuana subject to state-issued medical marijuana licenses, into Schedule III of the Controlled Substances Act. The news ran in every trucking trade outlet within forty-eight hours, and drivers started calling safety managers with the same question: is my marijuana use OK now?
For any safety-sensitive employer covered by federal drug testing rules, the answer is no.
If you employ CDL drivers or other safety-sensitive workers regulated by the DOT, marijuana is still a prohibited substance and your responsibilities have not changed. DEA scheduling moved for narrow categories of marijuana-related products. The DOT drug testing framework did not move at all.
There is more to it than that, though — particularly because the confusion is producing real consequences for carriers in the form of positive tests and Clearinghouse violations from drivers who believed the rules had changed.
Marijuana scheduling and DOT drug testing are two separate tracks that move at different speeds. Seeing them side by side is the fastest way to understand why a dramatic-sounding DEA announcement changes nothing in your testing program.
| Date | What happened | Effect on DOT drug testing |
|---|---|---|
| 1991 | Omnibus Transportation Employee Testing Act | Created the statutory basis for DOT testing |
| 1994 onward | 49 CFR Part 40 established and amended | Sets procedures, panel and cutoffs. Only ODAPC can change it |
| 2018 | DOT expands the opioid panel | Added hydrocodone, hydromorphone, oxycodone, oxymorphone. A DOT action |
| Jan 2020 | FMCSA Drug & Alcohol Clearinghouse launches | Violations become centrally visible; queries become mandatory |
| 2023 | Oral fluid authorized as a DOT collection method | Collection option changes; panel and consequences do not |
| Nov 18, 2024 | Clearinghouse II takes effect | States must downgrade the CDL of a driver in prohibited status |
| Apr 28, 2026 | DEA final order: FDA-approved marijuana products and state-licensed medical marijuana move to Schedule III | None. Part 40 unchanged |
| Jun 29, 2026 | Administrative hearing opens on the broader proposal to reschedule marijuana generally | None by itself. A CSA schedule change does not amend Part 40 |
| Any future date | Broader rescheduling, if it happens | Still none, unless and until DOT amends Part 40 through its own rulemaking |
The pattern in the right-hand column is the point. In thirty-five years, the things that actually changed DOT testing were all DOT actions — a new collection method, a new panel, a new database. No DEA scheduling decision has ever moved it.
This is the mechanism worth understanding once, because it answers every future version of this question.
Drug scheduling and drug testing are set by different agencies under different authority:
Part 40 does not say "test for Schedule I substances." It names the substances directly and sets cutoff concentrations for each. Because the list is explicit rather than a reference to a schedule, moving a substance between schedules leaves the testing panel untouched.
Changing the panel or the cutoffs requires ODAPC to act, coordinated with the Department of Health and Human Services through the Mandatory Guidelines for Federal Workplace Drug Testing Programs. The DOT program is anchored in the Omnibus Transportation Employee Testing Act of 1991, and that coordination is deliberate and slow — ODAPC has historically waited for HHS guideline updates and its own assessment of operational impact before touching Part 40.
Part 40 is then enforced through each modal administration's own rule:
| Mode | Rule |
|---|---|
| FMCSA (motor carriers) | 49 CFR Part 382 |
| FAA (aviation) | 49 CFR Part 120 |
| FRA (rail) | 49 CFR Part 219 |
| FTA (transit) | 49 CFR Part 655 |
| PHMSA (pipeline) | 49 CFR Part 199 |
DEA writes none of these. The April 28th order does not direct DOT to do anything, and DOT has announced no change.
So the rule to carry forward is simple: watch DOT, not DEA. A DEA announcement is news. A Part 40 amendment is a change to your program. In practical terms that means: do not rebuild your policy this week, do not retrain supervisors on a "new" standard, and do not soften your driver communications.
The action is in the Federal Register as FR-2026-08176, "Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III," issued as a Final Order by the Acting Attorney General under Department of Justice authority.
The order is grounded in DEA's view of United States obligations under the Single Convention on Narcotic Drugs of 1961. DEA explains that the CSA is the primary mechanism by which the US carries out those treaty obligations, and that the rule places covered products in the schedule DEA considers appropriate while maintaining required controls.
It does three concrete things:
And it reaches two categories only. Marijuana as defined in the CSA, marijuana extracts, delta-9-tetrahydrocannabinol and other compounds derived from the marijuana plant that fall outside the hemp definition — but only to the extent those substances are either included in an FDA-approved drug product, or subject to a state-issued license to manufacture, distribute or dispense marijuana for medical purposes.
Three things did not happen on April 28th, and the distinction matters for every safety manager fielding driver questions.
It was not a blanket rescheduling of all marijuana. Marijuana outside those two categories — unlicensed bulk marijuana, and marijuana neither incorporated into an FDA-approved product nor covered by a state medical license — remains subject to Schedule I controls.
It did not make state recreational marijuana federally legal, and it did not remove federal controls from state medical marijuana activity. It created a federal Schedule III framework for state-licensed medical marijuana, with an expedited registration route, while preserving federal registration, recordkeeping and permit requirements.
It did not change any DOT rule. Which is the part that matters most here.
DOT drug and alcohol testing lives in 49 CFR Part 40 — the procedures, the panel, the cutoff levels, the Medical Review Officer's role, and the verification process — enforced through each modal rule listed above.
Part 40 treats a confirmed marijuana positive — a specimen verified at or above the THC metabolite cutoff — as a violation regardless of the substance's CSA schedule. There is no exception for an FDA-approved Schedule III marijuana product, none for a state medical marijuana card, and none for any product that crosses the federal-state seam.
The clearest way to communicate this to a driver workforce is to enumerate what is unchanged:
Drivers ask first, and they ask informally — to dispatchers, to peers at the truck stop, to whoever picks up the phone. A driver hearing "marijuana is Schedule III now" is assuming it means something changed for them. The accurate answer, which they will not get from a casual conversation, is that marijuana use remains a violation for safety-sensitive positions regardless of state law, regardless of a medical card, and regardless of the rescheduling.
Safety managers and DOT compliance officers get the harder questions: what about a driver with a state medical card, and what about a driver prescribed an FDA-approved marijuana product such as Epidiolex. Both have specific answers under Part 40, below.
Medical Review Officers and Substance Abuse Professionals will field questions about verification and the return-to-duty path. Neither has changed. The MRO cannot accept a state card as a legitimate medical explanation, and the RTD framework is untouched.
Insurance partners and brokers may ask whether your risk profile has shifted. It has not, provided your program is running as it was.
"Is marijuana legal for me now?" No. The order reclassifies FDA-approved marijuana products and addresses state-licensed medical marijuana activity. It does not legalize recreational use and does not create a federal right to use marijuana. For a safety-sensitive driver the prohibited-use rules are unchanged.
"Does this change my DOT drug test or my random pool?" No. The panel, cutoffs and procedures are unchanged, and random selection continues exactly as before.
"I have a state medical marijuana card. Does that protect me?" No. A state card has never been a valid medical explanation for a positive DOT test, and that has not changed. The MRO cannot accept it.
"What if I'm prescribed an FDA-approved cannabis medication?" Treat it like any other prescription that may affect safety-sensitive work: disclose it during the MRO review process if relevant, and follow medical-examiner guidance on safe CMV operation. The rescheduling does not change the Part 40 verification framework.
A driver using an FDA-approved cannabinoid medication. Handle as above — disclosure through the MRO process, examiner guidance on fitness to drive. The key point is that the medication's Schedule III status does not create a defense to a positive marijuana test.
A driver with a state medical card using smoked or vaporized marijuana. This is the posture ODAPC has addressed directly and repeatedly. The card is not a legitimate medical explanation. The MRO verifies the positive, Clearinghouse reporting proceeds, and the return-to-duty process applies.
A driver in a recreationally legal state. Identical federal position. State legality has never been relevant to Part 40 and still is not.
Many employers run two programs in parallel — a DOT program for safety-sensitive employees and a company-policy program for everyone else. The order changes neither. A private employer's testing policy is a matter of company policy and applicable state law, not the federal drug schedule. If your company program references the DOT panel by design, it continues as written unless you choose to revise it.
In practice the order has more effect on non-safety-sensitive staff than on drivers, so it is worth a conversation with HR even though nothing on the DOT side moves.
Owner-operators face the same bottom line. An owner-operator holding a CDL and performing safety-sensitive functions is subject to the same Part 382 prohibited-use rules and the same testing program, typically through a consortium or C/TPA. The reclassification loosens nothing.
This week — communicate to drivers, plainly. A short direct message beats a long policy memo. Federal scheduling changed for one narrow category of marijuana products; DOT drug and alcohol testing did not change; marijuana use remains a violation for any safety-sensitive position covered by Part 40. Use the language drivers will encounter at the truck stop, not the language of a compliance manual. Two paragraphs is enough. Brief dispatch supervisors the same day so the floor message is consistent.
Within 30 days — tighten your policy language. Pull the drug and alcohol policy out of the handbook and find every reference to marijuana. Confirm it frames the prohibition correctly: prohibited under DOT testing for safety-sensitive positions regardless of state law and regardless of federal scheduling. If your policy ties consequences to "Schedule I status," reword it to tie to "a verified positive under 49 CFR Part 40" — that phrasing survives any future scheduling change. This is the one genuine action item the order creates.
Within 30 days — coordinate with HR on non-DOT staff, where the order has more practical effect.
Within 30 days — confirm with your MRO that their verification protocol is current, and with your collection vendor that nothing in their process has drifted.
Document the communication. Note in your drug and alcohol program file that you reviewed the order, confirmed no Part 40 impact, and communicated to the workforce. That record helps in an audit.
The April 28th order is separate from the broader proceeding that has drawn most of the attention: the proposed rescheduling of marijuana generally from Schedule I to Schedule III. That matter has been moving through an administrative hearing process.
The important point for a compliance team is structural and does not depend on the outcome: even a broader rescheduling would not, by itself, amend Part 40. For the testing program to change, DOT would have to change Part 40 through its own rulemaking, coordinated with HHS. A CSA schedule change is not that.
So assign one person to track the proceeding and report material developments, and do not modify your panel, policy or procedures on the strength of a hearing record.
Did the federal law on marijuana change on April 28th? Partly, and narrowly. FDA-approved drug products containing marijuana and marijuana subject to state-issued medical licenses moved to Schedule III. Marijuana outside those two categories remains Schedule I. Nothing about the order legalizes marijuana federally.
Can my driver use marijuana now? No. Marijuana remains prohibited for safety-sensitive employees under 49 CFR Part 382, and a verified positive under Part 40 carries the same consequences it did before April 28th.
Does the order change the DOT drug test panel or the random pool? No. The five-panel still includes THC, the cutoffs at 49 CFR 40.87 are unchanged, and random selection continues as before.
What about a driver with a state medical marijuana card? A state card has never been a valid medical explanation for a positive DOT test and still is not. The MRO cannot accept it, the Clearinghouse report proceeds, and the return-to-duty process applies.
If a driver is prescribed an FDA-approved Schedule III marijuana product, does that change the result? No. Part 40 contains no exception for an FDA-approved Schedule III marijuana product. The driver should disclose the medication during MRO review and follow medical-examiner guidance, but Schedule III status is not a defense to a positive.
Does this affect FMCSA Clearinghouse reporting? No. Verified positives and refusals are reported as before, the driver becomes prohibited from safety-sensitive functions, and the prohibition stands until the return-to-duty process is completed and a negative RTD test is reported.
Does the MRO have new discretion for marijuana positives? No. The verification framework is unchanged, and rescheduling does not create a legitimate medical explanation where none existed.
Will return-to-duty change? No. SAP evaluation, education or treatment, the return-to-duty test and follow-up testing all continue under 49 CFR 40.305 and 40.307.
Do we need to retrain supervisors on reasonable-suspicion testing? No. The reasonable-suspicion standard and the training requirement are unchanged. What is worth doing is a short briefing so supervisors can answer driver questions consistently.
Should we update our drug and alcohol policy because of this order? Only the language, and only if it needs it. If your policy ties the marijuana prohibition to "Schedule I status," reword it to reference a verified positive under Part 40 instead. The prohibition itself does not change.
What happens if a CDL driver tests positive for marijuana now? The same as before: immediate removal from safety-sensitive functions, a Clearinghouse report, and no return to those duties until the full return-to-duty process is complete.
Does this change non-DOT or owner-operator testing? No. A company-policy program is governed by company policy and state law, not the federal schedule. Owner-operators holding a CDL remain subject to Part 382 and to the same testing obligations, usually through a consortium.